Skip to main
ACHV

ACHV Stock Forecast & Price Target

ACHV Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Achieve Life Sciences Inc. has an encouraging outlook due to the validated mechanism and robust clinical efficacy of cytisinicline, positioning it as a vital therapy in the smoking and vaping cessation market amidst rising youth usage rates. The projected sales of $1.6 billion, bolstered by the expansion into the vaping label and potential global market reach, highlight significant revenue growth prospects. Furthermore, cytisinicline's favorable safety profile and flexible dosing options enhance patient adherence and may contribute to sustainable share appreciation for Achieve Life Sciences.

Bears say

Achieve Life Sciences faces a negative outlook primarily due to concerns regarding the adoption rate of cytisinicline, despite its approval for smoking cessation treatment. Internal projections indicate that even if cytisinicline gains approval for cigarette smoking, the anticipated sales may fall short, with a revised peak market penetration for vaping declining from 10% to 8%. Additionally, evidence suggests that while cytisinicline shows promising efficacy in reducing nicotine withdrawal effects, the market may be saturated with alternative therapies, hindering the drug's commercial success.

ACHV has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Achieve Life Sciences (ACHV) Forecast

Analysts have given ACHV a Buy based on their latest research and market trends.

According to 2 analysts, ACHV has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Achieve Life Sciences (ACHV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.